{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:34:00Z","timestamp":1764002040719,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.clml.2015.08.088","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T22:38:06Z","timestamp":1441233486000},"page":"711-714","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities"],"prefix":"10.1016","volume":"15","author":[{"given":"Stuart L.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.08.088_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.08.088_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.7073","article-title":"ENESTnd 5-year update: Long-term outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib vs. imatinib","volume":"32","author":"Larson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.08.088_bib3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final Study results of the phase 3 Dasatinib vs. Imatinib in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) trial (DASISION, CA180\u2013056)","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.088_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2015.08.088_bib5","article-title":"Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia","volume":"114","author":"St Charles","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.088_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2015.08.088_bib7","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.088_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.6119","article-title":"Prescription compliance and persistency in chronic myelogenous leukemia and gastrointestinal stromal tumor patients on imatinib","volume":"24","author":"Tsang","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.08.088_bib9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.4432.4432","article-title":"Adherence to oral tyrosine kinase inhibitor therapy: results of a self-reported patient survey","volume":"118","author":"Goldberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.088_bib10","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.08.088_bib11","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"year":"2015","series-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia, version 1.2015","key":"10.1016\/j.clml.2015.08.088_bib12"},{"key":"10.1016\/j.clml.2015.08.088_bib13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.088_bib14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1185\/03007995.2013.812034","article-title":"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib","volume":"29","author":"Goldberg","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2015.08.088_bib15","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1185\/03007995.2012.741577","article-title":"Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis","volume":"28","author":"Chen","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2015.08.088_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"Gu\u00e9rin","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2015.08.088_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2040620714560305","article-title":"The role of observational studies in optimizing the clinical management of chronic myeloid leukemia","volume":"6","author":"Mauro","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2015.08.088_bib18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3750.3750","article-title":"First-line treatment and management of chronic myeloid leukemia in clinical practice: update of > 1800 patients in the WORLD CML Registry","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.088_bib19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.2781.2781","article-title":"Understanding United States treatment practices for the management of chronic myeloid leukemia in clinical practice: a US subgroup analysis of the WORLD CML Registry","volume":"120","author":"Hermann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.08.088_bib20","article-title":"Cytogenetic and molecular testing in patients with chronic myeloid leukemia in a prospective observational study (SIMPLICITY)","volume":"32","author":"Goldberg","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.08.088_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1185\/03007995.2013.858621","article-title":"Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting","volume":"30","author":"Saleh","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2015.08.088_bib22","first-page":"89","article-title":"Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia","volume":"17","author":"Gu\u00e9rin","year":"2014","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clml.2015.08.088_bib23","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1200\/JOP.2014.001099","article-title":"Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia","volume":"11","author":"Goldberg","year":"2015","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2015.08.088_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.7065","article-title":"Treatment response monitoring in chronic phase CML (CP-CML) patients receiving tyrosine kinase inhibitor therapy in US Oncology network","volume":"31","author":"Kolibaba","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.08.088_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JOP.2013.001210","article-title":"Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system","volume":"10","author":"Hoverman","year":"2014","journal-title":"J\u00a0Oncol Pract"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501501246X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501501246X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:01Z","timestamp":1761870421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501501246X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S215226501501246X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.08.088","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring Chronic Myeloid Leukemia in the Real World: Gaps and Opportunities","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.08.088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}